1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
[CROSSREF] [PUBMED]
2. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care 2013;36:1033-1046.
[CROSSREF] [PUBMED] [PMC]
3. The Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Diabetes fact sheet in Korea 2013. Seoul: Korean Diabetes Association; 2013.
4. Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006;82:280-284.
[CROSSREF] [PUBMED] [PMC]
5. Yatsuya H, Li Y, Hilawe EH, Ota A, Wang C, Chiang C, et al. Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J 2014;78:2807-2818.
[CROSSREF] [PUBMED]
6. Shera AS, Jawad F, Maqsood A, Jamal S, Azfar M, Ahmed U. Prevalence of chronic complications and associated factors in type 2 diabetes. J Pak Med Assoc 2004;54:54-59.
[PUBMED]
7. Ridderstrale M, Gudbjornsdottir S, Eliasson B, Nilsson PM, Cederholm J. Steering Committee of the Swedish National Diabetes Register (NDR). Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 2006;259:314-322.
[CROSSREF] [PUBMED]
8. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-2140.
[CROSSREF] [PUBMED]
9. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011;34:1249-1257.
[CROSSREF] [PUBMED] [PMC]
10. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010;375:408-418.
[CROSSREF] [PUBMED]
11. Boffetta P, McLerran D, Chen Y, Inoue M, Sinha R, He J, et al. Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One 2011;6:e19930
[CROSSREF] [PUBMED] [PMC]
12. Hsu WC, Araneta MR, Kanaya AM, Chiang JL, Fujimoto W. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care 2015;38:150-158.
[CROSSREF] [PUBMED]
13. Pan WH, Yeh WT. How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations. Asia Pac J Clin Nutr 2008;17:370-374.
[PUBMED]
14. Choi HS, Oh HJ, Choi H, Choi WH, Kim JG, Kim KM, et al. Vitamin D insufficiency in Korea: a greater threat to younger generation: the Korea National Health and Nutrition Examination Survey (KNHANES) 2008. J Clin Endocrinol Metab 2011;96:643-651.
[CROSSREF] [PUBMED] [PDF]
15. American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care 2014;37(Suppl 1):S14-S80.
[CROSSREF] [PUBMED]
16. Rhee BD. Epidemiological characteristics of diabetes mellitus among Korean population. J Korean Diabetes Assoc 2003;27:173-178.
17. Ganz ML, Wintfeld N, Li Q, Alas V, Langer J, Hammer M. The association of body mass index with the risk of type 2 diabetes: a case-control study nested in an electronic health records system in the United States. Diabetol Metab Syndr 2014;6:50
[CROSSREF] [PUBMED] [PMC]
18. Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006. Obes Surg 2011;21:351-355.
[CROSSREF] [PUBMED]
19. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-846.
[CROSSREF] [PUBMED] [PDF]
20. Kavouras SA, Panagiotakos DB, Pitsavos C, Chrysohoou C, Anastasiou CA, Lentzas Y, et al. Physical activity, obesity status, and glycemic control: The ATTICA study. Med Sci Sports Exerc 2007;39:606-611.
[CROSSREF] [PUBMED]
21. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-1688.
[CROSSREF] [PUBMED]
22. Araneta MR, Kanaya AM, Hsu WC, Chang HK, Grandinetti A, Boyko EJ, et al. Optimum BMI cut points to screen asian americans for type 2 diabetes. Diabetes Care 2015;38:814-820.
[CROSSREF] [PUBMED] [PMC]
23. Low S, Chin MC, Ma S, Heng D, Deurenberg-Yap M. Rationale for redefining obesity in Asians. Ann Acad Med Singapore 2009;38:66-69.
[PUBMED]
24. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006;355:763-778.
[CROSSREF] [PUBMED]
25. Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300,000 persons. Arch Intern Med 2007;167:1720-1728.
[CROSSREF] [PUBMED]
26. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, et al. Body-mass index and mortality in Korean men and women. N Engl J Med 2006;355:779-787.
[CROSSREF] [PUBMED]
27. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA. Mortality in people with type 2 diabetes in the UK. Diabet Med 2006;23:516-521.
[CROSSREF]
28. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Nunez L, Gudbjornsdóttir S, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009;52:65-73.
[CROSSREF] [PUBMED] [PDF]
29. Chen Y, Copeland WK, Vedanthan R, Grant E, Lee JE, Gu D, et al. Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ 2013;347:f5446
[CROSSREF] [PUBMED] [PMC]
30. Look AHEAD Research Group. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30:1374-1383.
[CROSSREF] [PUBMED] [PMC]
31. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-742.
[CROSSREF] [PUBMED] [PDF]
32. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635.
[CROSSREF] [PUBMED]
33. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091.
[CROSSREF] [PUBMED]
34. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100.
[CROSSREF] [PUBMED]
35. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569.
[CROSSREF] [PUBMED]
36. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481.
[CROSSREF] [PUBMED]
37. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278.
[CROSSREF] [PUBMED] [PMC]